Coherus Acquires Bevacizumab Rights From Innovent
Deal Also Includes Option To Sell Innovent’s Rituximab Biosimilar
Coherus BioSciences has struck a deal with China’s Innovent Biologics that gives it US and Canadian rights to a bevacizumab biosimilar version of Avastin as well as an option to market Innovent’s rituximab rival to Rituxan in the US and Canada.
